To discuss the standard of care and the use of ZAVZPRET (zavegepant), the first and only CGRP receptor antagonist nasal spray for the acute treatment of migraines developed by Pfizer.
This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third View: Checking in with a prescriber of ZAVZPRET (zavegepant) from Pfizer for the acute treatment of Migraines
Ticker(s): PFEWho's the expert?
Institution: Phoenix Headache Institute
- Director of The Phoenix Headache Institute, Founder & President of Gila Sciences, Assistant Clinical Professor at Midwestern University, and Clinical faculty at Honor Healthcare.
- Manages ~2,000 migraine patients within his practice.
- Has prescribed Zavzpret to approximately 15 patients.
Interview Goal
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
